XOMA has been granted a patent for a combination therapy using inhibitors of transforming growth factor beta (TGFß) and programmed cell death protein 1 (PD-1) for treating and preventing recurrence of various cancer diseases, including lung, prostate, breast, and ovarian cancer. The method involves administering therapeutically effective amounts of the inhibitors to increase the ratio of effector T cells to regulatory T cells in tumors. The TGFß inhibitor is an antibody with specific amino acid sequences. GlobalData’s report on XOMA gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on XOMA, NSAID cancer drugs was a key innovation area identified from patents. XOMA's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for treating cancer using tgfß and pd-1 inhibitors
A recently granted patent (Publication Number: US11685775B2) describes a method for increasing the ratio of effector T cells to regulatory T cells in a tumor. The method involves administering therapeutically effective amounts of an inhibitor of transforming growth factor beta (TGFß) and an antibody that binds Programmed cell death protein 1 (PD-1) to a subject in need. The TGFß inhibitor is an antibody that binds to TGFß1, TGFß2, and TGFß3.
The patent claims specify the amino acid sequences of the TGFß inhibitor antibody, including the heavy chain CDR1, CDR2, and CDR3 sequences, as well as the light chain CDR1, CDR2, and CDR3 sequences. The TGFß antibody is designed to bind to TGFß1 and TGFß2 with greater affinity than to TGFß3. It also neutralizes the activity of TGFß1 and TGFß2 to a greater extent than TGFß3. The affinity of the antibody for TGFß1, TGFß2, and TGFß3 is within the range of 10-6 M to 10-12 M.
The antibody used in the method has variable regions that are at least 90% identical to specific amino acid sequences. The patent also describes different combinations of heavy and light chain variable region amino acid sequences for the antibody.
The method is applicable to various types of tumors, including esophageal cancer, pancreatic cancer, bladder cancer, stomach cancer, glioma, renal cell carcinoma, prostate cancer, melanoma, lung cancer, breast cancer, hepatocellular carcinoma, lymphoma, leukemia, colorectal cancer, and many others.
The method aims to reduce tumor size or tumor burden in the subject and also reduce metastasis. The tumor size reduction is expected to be at least 20%. The TGFß inhibitor and PD-1 antibody can be formulated in a pharmaceutical composition and administered at different frequencies, ranging from once daily to once every two months. The recommended dose range for the TGFß inhibitor and PD-1 antibody is 0.1 to 15 mg/kg.
In summary, the granted patent describes a method for increasing the ratio of effector T cells to regulatory T cells in a tumor by administering a combination of a TGFß inhibitor and a PD-1 antibody. The method has potential applications in various types of tumors and aims to reduce tumor size and metastasis. The patent provides specific amino acid sequences for the TGFß inhibitor antibody and suggests different dosing regimens for its administration.